Breast cancer was generally thought to have a weak immunogenicity, but recent studies have demonstrated high levels of TILs occurring in HER2+ and basal-like subtypes which are associated with good prognosis and with response to certain therapies (6, 7). The gene discussed is ERBB2; the disease is breast cancer.